(Q48237778)

9 February 2018

title

B-type natriuretic peptide in cardiovascular disease. (English)

1 reference

9 February 2018

main subject

cardiovascular disease

1 reference

2

Darren K McGuire

1 reference

9 February 2018

James A. de Lemos

series ordinal

1

object named as

James A de Lemos

1 reference

9 February 2018

author name string

Mark H Drazner

series ordinal

3

1 reference

9 February 2018

language of work or name

English

0 references

publication date

1 July 2003

1 reference

9 February 2018

published in

The Lancet

1 reference

9 February 2018

volume

362

1 reference

9 February 2018

issue

9380

1 reference

9 February 2018

page(s)

316-322

1 reference

9 February 2018

The possible role of cardiac atrial stretch receptors in the induction of changes in urine flow

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2913976-1

7 January 2021

A rapid and potent natriuretic response to intravenous injection of atrial myocardial extract in rats

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2913976-1

7 January 2021

Purification and complete amino acid sequence of beta-rat atrial natriuretic polypeptide (β-rANP) of 5,000 daltons

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2913976-1

7 January 2021

A new natriuretic peptide in porcine brain.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2913976-1

7 January 2021

Expression of brain natriuretic peptide gene in human heart. Production in the ventricle.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2913976-1

7 January 2021

Localization and mechanism of secretion of B-type natriuretic peptide in comparison with those of A-type natriuretic peptide in normal subjects and patients with heart failure.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2913976-1

7 January 2021

C-type natriuretic peptide (CNP): a new member of natriuretic peptide family identified in porcine brain.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2913976-1

7 January 2021

Characterization of immunoreactive human C-type natriuretic peptide in brain and heart

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2913976-1

7 January 2021

Atrial stretch, not pressure, is the principal determinant controlling the acute release of atrial natriuretic factor

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2913976-1

7 January 2021

Gene expression of brain natriuretic peptide in isolated atrial and ventricular human myocardium: influence of angiotensin II and diastolic fiber length.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2913976-1

7 January 2021

Plasma levels of A- and B-type natriuretic peptides in patients with hypertrophic cardiomyopathy or idiopathic dilated cardiomyopathy

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2913976-1

7 January 2021

Neuropeptide secretion in exercise.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2913976-1

7 January 2021

Rapid ventricular induction of brain natriuretic peptide gene expression in experimental acute myocardial infarction

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2913976-1

7 January 2021

Different secretion patterns of atrial natriuretic peptide and brain natriuretic peptide in patients with congestive heart failure.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2913976-1

7 January 2021

Natriuretic peptides in patients with aortic stenosis.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2913976-1

7 January 2021

Biosynthesis, secretion, and receptor selectivity of human brain natriuretic peptide

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2913976-1

7 January 2021

Expression and distribution of brain natriuretic peptide in human right atria.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2913976-1

7 January 2021

Localization of brain and atrial natriuretic peptide in human and porcine heart.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2913976-1

7 January 2021

Atrial Natriuretic Peptide and Brain Natriuretic Peptide Coexist in the Secretory Granules of Human Cardiac Myocytes

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2913976-1

7 January 2021

Comparison of secretion pattern between A-type and B-type natriuretic peptides in patients with old myocardial infarction

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2913976-1

7 January 2021

Dexamethasone-induced up-regulation of adrenomedullin and atrial natriuretic peptide genes in cultured rat ventricular myocytes

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2913976-1

7 January 2021

Modulation of atrial natriuretic factor by thyroid hormone: messenger ribonucleic acid and peptide levels in hypothyroid, euthyroid, and hyperthyroid rat atria and ventricles

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2913976-1

7 January 2021

Receptor selectivity of natriuretic peptide family, atrial natriuretic peptide, brain natriuretic peptide, and C-type natriuretic peptide

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2913976-1

7 January 2021

Brain natriuretic peptide as a novel cardiac hormone in humans. Evidence for an exquisite dual natriuretic peptide system, atrial natriuretic peptide and brain natriuretic peptide

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2913976-1

7 January 2021

Identification of protease 3.4.24.11 as the major atrial natriuretic factor degrading enzyme in the rat kidney

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2913976-1

7 January 2021

Atrial natriuretic peptide causes pre-glomerular vasodilatation and post-glomerular vasoconstriction in rat kidney

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2913976-1

7 January 2021

Atrial natriuretic hormone has biological effects in man at physiological plasma concentrations

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2913976-1

7 January 2021

Low-dose infusion of atrial natriuretic factor in mild essential hypertension.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2913976-1

7 January 2021

Sympathoinhibitory effects of atrial natriuretic factor in normal humans.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2913976-1

7 January 2021

Effects of intravenous brain natriuretic peptide on regional sympathetic activity in patients with chronic heart failure as compared with healthy control subjects

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2913976-1

7 January 2021

Effect of atrial peptides on aldosterone production

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2913976-1

7 January 2021

Brain natriuretic peptide: effect on left ventricular filling patterns in healthy subjects

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2913976-1

7 January 2021

Atrial natriuretic polypeptide inhibits hypertrophy of vascular smooth muscle cells

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2913976-1

7 January 2021

Natriuretic peptides inhibit DNA synthesis in cardiac fibroblasts.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2913976-1

7 January 2021

Endothelial production of C-type natriuretic peptide and its marked augmentation by transforming growth factor-beta. Possible existence of "vascular natriuretic peptide system"

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2913976-1

7 January 2021

Central C-type natriuretic peptide augments the hormone response to hemorrhage in conscious sheep

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2913976-1

7 January 2021

Plasma brain natriuretic peptide in assessment of acute dyspnoea.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2913976-1

7 January 2021

Value of natriuretic peptides in assessment of patients with possible new heart failure in primary care

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2913976-1

7 January 2021

Superiority of brain natriuretic peptide as a hormonal marker of ventricular systolic and diastolic dysfunction and ventricular hypertrophy.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2913976-1

7 January 2021

Plasma brain natriuretic peptide as an indicator of left ventricular systolic function and long-term survival after acute myocardial infarction. Comparison with plasma atrial natriuretic peptide and N-terminal proatrial natriuretic peptide

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2913976-1

7 January 2021

Head-to-head comparison of N-terminal pro-brain natriuretic peptide, brain natriuretic peptide and N-terminal pro-atrial natriuretic peptide in diagnosing left ventricular dysfunction

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2913976-1

7 January 2021

Utility of B-type natriuretic peptide in the diagnosis of congestive heart failure in an urgent-care setting

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2913976-1

7 January 2021

Utility of a rapid B-natriuretic peptide assay in differentiating congestive heart failure from lung disease in patients presenting with dyspnea

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2913976-1

7 January 2021

Rapid measurement of B-type natriuretic peptide in the emergency diagnosis of heart failure

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2913976-1

7 January 2021

B-type natriuretic peptide and clinical judgment in emergency diagnosis of heart failure: analysis from Breathing Not Properly (BNP) Multinational Study

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2913976-1

7 January 2021

Screening for and treating left-ventricular abnormalities in diabetes mellitus: a new way of reducing cardiac deaths

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2913976-1

7 January 2021

Plasma brain natriuretic peptide as an indicator for angiotensin-converting-enzyme inhibition after myocardial infarction.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2913976-1

7 January 2021

Diagnostic potential of cardiac natriuretic peptides in dialysis patients.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2913976-1

7 January 2021

Brain natriuretic peptide is a predictor of anthracycline-induced cardiotoxicity

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2913976-1

7 January 2021

Plasma cardiac natriuretic peptide determination as a screening test for the detection of patients with mild left ventricular impairment

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2913976-1

7 January 2021

Evaluation of brain natriuretic peptide as marker of left ventricular dysfunction and hypertrophy in the population

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2913976-1

7 January 2021

Plasma natriuretic peptides for community screening for left ventricular hypertrophy and systolic dysfunction: the Framingham heart study.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2913976-1

7 January 2021

A rapid test for B-type natriuretic peptide correlates with falling wedge pressures in patients treated for decompensated heart failure: a pilot study

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2913976-1

7 January 2021

Brain natriuretic factor: regional plasma concentrations and correlations with haemodynamic state in cardiac disease

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2913976-1

7 January 2021

Expression of atrial and brain natriuretic peptides and their genes in hearts of patients with cardiac amyloidosis.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2913976-1

7 January 2021

Utility of B-natriuretic peptide as a rapid, point-of-care test for screening patients undergoing echocardiography to determine left ventricular dysfunction.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2913976-1

7 January 2021

Diastolic dysfunction and natriuretic peptides in systolic heart failure. Higher ANP and BNP levels are associated with the restrictive filling pattern.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2913976-1

7 January 2021

Utility of B-natriuretic peptide in detecting diastolic dysfunction: comparison with Doppler velocity recordings

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2913976-1

7 January 2021

Plasma brain natriuretic peptide levels increase in proportion to the extent of right ventricular dysfunction in pulmonary hypertension.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2913976-1

7 January 2021

Elevated plasma brain natriuretic peptide levels in chronic respiratory failure with cor pulmonale.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2913976-1

7 January 2021

Neurohormonal activation and the chronic heart failure syndrome in adults with congenital heart disease

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2913976-1

7 January 2021

Diagnostic value of plasma levels of brain natriuretic peptide in arrhythmogenic right ventricular dysplasia

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2913976-1

7 January 2021

Impact of age and sex on plasma natriuretic peptide levels in healthy adults.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2913976-1

7 January 2021

Plasma brain natriuretic peptide concentration: impact of age and gender

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2913976-1

7 January 2021

Neurohumoral prediction of benefit from carvedilol in ischemic left ventricular dysfunction. Australia-New Zealand Heart Failure Group

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2913976-1

7 January 2021

High levels of plasma brain natriuretic peptide and interleukin-6 after optimized treatment for heart failure are independent risk factors for morbidity and mortality in patients with congestive heart failure

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2913976-1

7 January 2021

Prognostic evaluation of neurohumoral plasma levels before and during beta-blocker therapy in advanced left ventricular dysfunction

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2913976-1

7 January 2021

Prognostic value of neurohormonal activation and cardiopulmonary exercise testing in patients with chronic heart failure

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2913976-1

7 January 2021

B-type natriuretic peptide predicts sudden death in patients with chronic heart failure

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2913976-1

7 January 2021

Plasma N-terminal pro-brain natriuretic peptide and adrenomedullin: prognostic utility and prediction of benefit from carvedilol in chronic ischemic left ventricular dysfunction. Australia-New Zealand Heart Failure Group

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2913976-1

7 January 2021

B-type natriuretic peptide predicts future cardiac events in patients presenting to the emergency department with dyspnea

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2913976-1

7 January 2021

Outcomes after emergency department discharge with a primary diagnosis of heart failure

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2913976-1

7 January 2021

A rapid bedside test for B-type peptide predicts treatment outcomes in patients admitted for decompensated heart failure: a pilot study.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2913976-1

7 January 2021

Plasma brain natriuretic peptide is a biochemical marker for the prediction of progressive ventricular remodeling after acute myocardial infarction.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2913976-1

7 January 2021

Plasma N-terminal pro-brain natriuretic peptide and adrenomedullin: new neurohormonal predictors of left ventricular function and prognosis after myocardial infarction

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2913976-1

7 January 2021

The prognostic value of B-type natriuretic peptide in patients with acute coronary syndromes.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2913976-1

7 January 2021

Prognostic value of N-terminal pro-atrial and pro-brain natriuretic peptide in patients with acute coronary syndromes

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2913976-1

7 January 2021

N-terminal pro brain natriuretic peptide on admission for early risk stratification of patients with chest pain and no ST-segment elevation.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2913976-1

7 January 2021

Plasma concentration of brain natriuretic peptide as a biochemical marker for the evaluation of right ventricular overload and mortality in chronic respiratory disease.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2913976-1

7 January 2021

Plasma brain natriuretic peptide as a prognostic indicator in patients with primary pulmonary hypertension

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2913976-1

7 January 2021

Brain natriuretic peptide predicts mortality in the elderly

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2913976-1

7 January 2021

Left ventricular dysfunction, natriuretic peptides, and mortality in an urban population

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2913976-1

7 January 2021

Neurohormonal activation rapidly decreases after intravenous therapy with diuretics and vasodilators for class IV heart failure

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2913976-1

7 January 2021

High- versus low-dose ACE inhibition in chronic heart failure: a double-blind, placebo-controlled study of imidapril.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2913976-1

7 January 2021

Titration of vasodilator therapy in chronic heart failure according to plasma brain natriuretic peptide concentration: randomized comparison of the hemodynamic and neuroendocrine effects of tailored versus empirical therapy.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2913976-1

7 January 2021

Effects of valsartan on circulating brain natriuretic peptide and norepinephrine in symptomatic chronic heart failure: the Valsartan Heart Failure Trial (Val-HeFT).

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2913976-1

7 January 2021

Effect of spironolactone on plasma brain natriuretic peptide and left ventricular remodeling in patients with congestive heart failure

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2913976-1

7 January 2021

Release of atrial natriuretic factor during selective cardiac alpha- and beta-adrenergic stimulation, intracoronary Ca2+ infusion, and aortic constriction in pigs

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2913976-1

7 January 2021

Effect of low dose beta blockers on atrial and ventricular (B type) natriuretic factor in heart failure: a double blind, randomised comparison of metoprolol and a third generation vasodilating beta blocker

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2913976-1

7 January 2021

Effects of metoprolol CR in patients with ischemic and dilated cardiomyopathy : the randomized evaluation of strategies for left ventricular dysfunction pilot study

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2913976-1

7 January 2021

Plasma brain natriuretic peptide as a novel therapeutic indicator in idiopathic dilated cardiomyopathy during beta-blocker therapy: a potential of hormone-guided treatment

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2913976-1

7 January 2021

Role of brain natriuretic peptide in risk stratification of patients with congestive heart failure.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2913976-1

7 January 2021

Treatment of heart failure guided by plasma aminoterminal brain natriuretic peptide (N-BNP) concentrations

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2913976-1

7 January 2021

The effects of pathophysiological increments in brain natriuretic peptide in left ventricular systolic dysfunction

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2913976-1

7 January 2021

Hemodynamic effects of a single intravenous injection of synthetic human brain natriuretic peptide in patients with heart failure secondary to ischemic or idiopathic dilated cardiomyopathy.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2913976-1

7 January 2021

Hemodynamic and renal excretory effects of human brain natriuretic peptide infusion in patients with congestive heart failure. A double-blind, placebo-controlled, randomized crossover trial.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2913976-1

7 January 2021

Systemic hemodynamic, neurohormonal, and renal effects of a steady-state infusion of human brain natriuretic peptide in patients with hemodynamically decompensated heart failure.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2913976-1

7 January 2021

Intravenous nesiritide, a natriuretic peptide, in the treatment of decompensated congestive heart failure. Nesiritide Study Group.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2913976-1

7 January 2021

Comparison of the occurrence of ventricular arrhythmias in patients with acutely decompensated congestive heart failure receiving dobutamine versus nesiritide therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2913976-1

7 January 2021

The role of neutral endopeptidase in dogs with evolving congestive heart failure

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2913976-1

7 January 2021

Vasopeptidase inhibitors: a new therapeutic concept in cardiovascular disease?

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2913976-1

7 January 2021

Omapatrilat reduces pulse pressure and proximal aortic stiffness in patients with systolic hypertension: results of the conduit hemodynamics of omapatrilat international research study

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2913976-1

7 January 2021

The clinical, cardiac, renal, arterial and neurohormonal effects of omapatrilat, a vasopeptidase inhibitor, in patients with chronic heart failure

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2913976-1

7 January 2021

Effects of omapatrilat on hemodynamics and safety in patients with heart failure

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2913976-1

7 January 2021

Comparison of vasopeptidase inhibitor, omapatrilat, and lisinopril on exercise tolerance and morbidity in patients with heart failure: IMPRESS randomised trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2913976-1

7 January 2021

Comparison of omapatrilat and enalapril in patients with chronic heart failure: the Omapatrilat Versus Enalapril Randomized Trial of Utility in Reducing Events (OVERTURE).

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2913976-1

7 January 2021

Vasopeptidase inhibition and angio-oedema

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2913976-1

7 January 2021

Results from late-breaking clinical trial sessions at the American College of Cardiology 51st Annual Scientific Session

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2913976-1

7 January 2021

10.1016/S0140-6736(03)13976-1

Identifiers

DOI

1 reference

9 February 2018

PubMed ID

12892964

1 reference

9 February 2018